A detailed history of Royal Bank Of Canada transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 2,760 shares of ITOS stock, worth $22,714. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,760
Previous 2,442 13.02%
Holding current value
$22,714
Previous $36,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.09 - $17.97 $3,208 - $5,714
318 Added 13.02%
2,760 $28,000
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $10,794 - $18,904
1,045 Added 74.8%
2,442 $36,000
Q1 2024

Nov 05, 2024

SELL
$9.89 - $13.64 $10,335 - $14,253
-1,045 Reduced 42.79%
1,397 $19,000
Q1 2024

May 15, 2024

SELL
$9.89 - $13.64 $54,909 - $75,729
-5,552 Reduced 79.9%
1,397 $19,000
Q4 2023

Feb 14, 2024

BUY
$8.57 - $11.06 $23,893 - $30,835
2,788 Added 67.0%
6,949 $76,000
Q3 2023

Nov 14, 2023

BUY
$10.95 - $14.6 $17,246 - $22,995
1,575 Added 60.9%
4,161 $45,000
Q2 2023

Aug 14, 2023

BUY
$12.93 - $18.05 $16,227 - $22,652
1,255 Added 94.29%
2,586 $34,000
Q1 2023

May 15, 2023

SELL
$13.02 - $22.62 $17,824 - $30,966
-1,369 Reduced 50.7%
1,331 $18,000
Q4 2022

Feb 14, 2023

BUY
$17.77 - $21.6 $42,559 - $51,732
2,395 Added 785.25%
2,700 $52,000
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $2,529 - $3,706
136 Added 80.47%
305 $5,000
Q2 2022

Aug 15, 2022

SELL
$16.57 - $35.1 $17,845 - $37,802
-1,077 Reduced 86.44%
169 $4,000
Q1 2022

May 16, 2022

SELL
$31.92 - $47.45 $69,138 - $102,776
-2,166 Reduced 63.48%
1,246 $40,000
Q4 2021

Feb 14, 2022

BUY
$26.23 - $47.86 $32,735 - $59,729
1,248 Added 57.67%
3,412 $158,000
Q3 2021

Nov 15, 2021

SELL
$23.91 - $29.58 $7,412 - $9,169
-310 Reduced 12.53%
2,164 $59,000
Q2 2021

Aug 16, 2021

BUY
$17.9 - $36.1 $44,284 - $89,311
2,474 New
2,474 $63,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.